• Cytori Therapeutics Inc., of San Diego, said six-month outcomes from its European Phase I/IIa APOLLO trial, published in the Journal of the American College of Cardiology, showed that the procedure for extracting adipose-derived stem and regenerative cells (ADRCs) and injecting them back into myocardial infarction patients could safely be performed in an acute setting, with no side effects from ADRC delivery processed using the firm's Celution System. Patients were injected within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention. Data from the study also showed improvement in cardiac function by SPECT, improvement in blood blow into the heart muscle and a reduction in scar formation. Cytori has started a pivotal trial, dubbed ADVANCE, which is enrolling up to 360 patients.

• DynPort Vaccine Co. LLC, of Falls Church, Va., said it completed a Phase II trial of its recombinant botulinum vaccine candidate, rBV A/B, showing that it was safe and well tolerated and elicited a strong immune response, with more than 94 percent of subjects maintaining detectable neutralizing antibody concentrations for at least one year after the third dose. The study enrolled 440 healthy adults and evaluated rBV A/B at two dosing schedules vs. placebo. The vaccine is being developed for the protection of adults, ages 18 to 55, from fatal botulism caused by inhalational intoxication with two serotypes of botulinum neurotoxin.

• Immatics Biotechnologies GmbH, of Tuebingen, Germany, reported Phase II data showing IMA910 was able to stimulate relevant immune responses against the tumor-associated peptides (TUMAPs) in the majority of vaccinated patients with advanced and/or metastatic colorectal cancer who had shown no progression following 12 weeks of first-line oxaliplatin-based chemotherapy. In patients who had detectable T-cell responses against two or more of the TUMAPs contained in IMA910, a consistently better clinical outcome was observed, compared to those who did not have detectable multi-T-cell responses. Patients who mounted both CD8-positive and CD4-positive multi-T-cell responses had not reached median survival after more than 28 months of follow-up vs. a 16-month median survival time for those who did not have both multi-T-cell responses. Data were presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium in San Francisco.